RYTM News and Press, Rhythm Pharmaceuticals Inc. From 05/07/24

2024-05-07 21:50:36 ET Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Results Conference Call May 07, 2024 8:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennifer Lee - ...

2024-05-07 07:20:21 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Action Too Specific Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript Rhythm Pharmaceuticals Q1 2024 Earnings Preview Phathom Pharma, Rhythm, Vaxcyte most likely ...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

-- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- --...

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- Company remains on track to ...

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, Apri...

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call ...

2024-04-14 11:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...

2024-04-01 08:12:19 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Action Too Specific Rhythm Pharmaceuticals reports mixed Q4 results; initiates FY24 outlook Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals Read the full article on ...